ClinicalTrials.gg
Not yet recruitingNCT07598565Updated May 22, 2026

The CORE - μFR Clinical Trial

An interventional study of Angiography-guided PCI and μFR based-PCI in Acute Coronary Syndromes (ACS), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction and STEMI - ST Elevation Myocardial Infarction, sponsored by University of Roma La Sapienza. Not yet recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University of Roma La Sapienza · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Acute Coronary Syndrome with a site in Italy — 25 open to participants now, 29 under way, 2 of them phase 3. Acute Coronary Syndrome · Italy.

Planned enrollment
49th of 85
350 · median 522
Started
2026
with 4 others
No phase
29 of 138
7 open now
Primary completion
2027-06
later than 16 of 28 live
Registered
135th of 138
by date

Among the 138 studies in Acute Coronary Syndrome with a site in Italy, this one is the 49th largest by planned enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2026, is one of 29 with no phase, reaches primary completion later than 16 of the 28 other live ones, and was the 135th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

25 of the 138 studies in Acute Coronary Syndrome with a site in Italy are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Acute Coronary Syndrome with a site in Italy, or all of them as a file.
02

Study summary

Acute coronary syndromes (ACS) are frequently associated with multivessel coronary artery disease (CAD), and current guidelines recommend complete revascularization beyond the culprit lesion. Angiography-guided PCI is the standard approach, but anatomical assessment does not always reflect the functional significance of intermediate lesions, while FFR-guided strategies are limited by the need for pressure wires and hyperemia. Murray-law-based quantitative flow ratio (μFR) is a wire-free angiography-derived physiological index that may improve decision-making for revascularization in ACS patients.

The Core-μFR is an investigator-driven, multicenter, randomized, open-label and prospective trial designed to evaluate whether μFR can act as a gatekeeper for complete revascularization in patients with ACS and multivessel disease by identifying non-culprit lesions that truly require PCI.

Patients with ACS (either STEMI or NSTE-ACS) undergoing primary PCI will be considered eligible if they present multivessel CAD on visual assessment with the intention to treat the non-culprit vessel in a staged procedure within the same hospitalization. After the pPCI, eligible patients will be randomized to either group A or group B and μFR will be performed in a blinded fashion with the operator unaware of the functional result. Patients in group A will undergo a staged PCI of all NCVs guided by coronary angiography, as per standard of care. In group B, μFR will be used as a gatekeeper for staged revascularization. Operators will only be informed whether at least one non-culprit vessel is μFR-positive, without disclosure of the specific vessel involved or the μFR values. If at least one non-culprit vessel has μFR ≤0.80, patients will undergo angiography-guided PCI of all non-culprit vessels previously deemed suitable for treatment by visual assessment. If μFR is >0.80 in all non-culprit vessels, staged PCI will be deferred and the patient will be discharged without further revascularization. Finally, to test the functional reproducibility, a blinded post-hoc μFR assessment will be performed on the baseline angiograms of the staged procedures in all the patients undergoing complete revascularization. Clinical follow-up will be performed at 30 days and 1 year from randomization.

03

Conditions studied

  • Acute Coronary Syndromes (ACS)
  • NSTEMI - Non-ST-Segment Elevation Myocardial Infarction
  • STEMI - ST Elevation Myocardial Infarction
  • Multivessel Coronary Artery Disease

Keywords

  • Murray-law based Quantitative Flow Ratio (μFR)
  • Non culprit vessel
  • Revascularization
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients presenting with ACS within 72 hours of successful culprit PCI
  2. Residual coronary artery disease, defined as at least one additional stenosis in any non-culprit vessel (NCV) with the following characteristics:

    1. at least 50% diameter stenosis by visual assessment
    2. a vessel diameter of at least 2.5 mm
    3. amenable to successful PCI

Exclusion criteria

Exclusion Criteria:

  1. Cardiogenic shock or severe heart failure ( class ≥III)
  2. Severely impaired renal function: creatinine >2 mg/dl or estimated (eGFR) \<30 ml/min/1,73 m²
  3. Allergy to iodine-containing contrast agents which cannot be adequately pre-medicated
  4. Pregnancy or intention to become pregnant during the trial
  5. less than one year
  6. Ambiguity in the identification of the culprit vessel/lesion
  7. Clinical presentation as myocardial infarction and non-obstructive coronary artery disease (MINOCA) and/or Tako-Tsubo Syndrome
  8. Any ambiguity in the diagnosis of ACS
  9. Inability to provide
  10. Patients with only one coronary artery lesion with diameter stenosis >90% and/or TIMI flow \<3
  11. Patients in whom the NCV is treated at the time of the index procedure
  12. An interrogated lesion is at the site of a myocardial bridge
  13. An interrogated lesion is a culprit lesion responsible for the acute myocardial infarction
  14. An interrogated lesion is in a bypass graft
  15. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification
  16. Severe vessel overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to μFR measurement
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Active comparator
    Group A - Angiography-guided PCI (standard strategy)

    Patients will undergo a staged PCI of all non-culprit vessels identified before randomization according to angiography and operator judgment, as per standard of care. μFR will be analyzed off-line by the core lab and will not be available to the operator.

    Procedure: Angiography-guided PCI

  • Experimental
    Group B - μFR based-PCI

    μFR will be analyzed off-line by the core lab. Coronary revascularization will be deferred if the μFR \> 0.80 in all the non-culprit vessels identified before randomization. If μFR ≤ 0.80 in at least one non-culprit vessels identified before randomization, patients will undergo a staged PCI. Operators remain blinded to μFR values, and treatment of vessels is based on angiography only.

    Procedure: μFR based-PCI

Interventions

  • ProcedureAngiography-guided PCI

    staged PCI of all NCVs will be performed as per standard of care

  • ProcedureμFR based-PCI

    staged PCI will be deferred if the μFR \> 0.80 in all the NCVs or performed if the μFR is ≤ 0.80 in at least one NCVs

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint

    Number of stents implanted and number of procedures

    Time frame: Periprocedural

  2. Primary safety endpoint

    MACE (major adverse cardiovascular event) defined as the composite of all-cause mortality, non-culprit vessel unplanned revascularization, non-fatal myocardial infarction (defined according to the Fourth Universal Definition of Myocardial Infarction, including procedural MI and spontaneous MI)

    Time frame: 1 year

Secondary outcomes

  1. Inappropriate revascularization

    Inappropriate revascularization according to μFR value

    Time frame: Periprocedural

  2. Change in clinical decision making

    Change in clinical decision making about revascularization strategy from intended PCI to medical therapy

    Time frame: Periprocedural

  3. μFR reproducibility

    Test-re-test repeatability of μFR

    Time frame: Periprocedural

  4. Length of stay

    Duration of hospitalization

    Time frame: Periprocedural

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jun 2027, 13 months later.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 13 months is below that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 20, 2026
StartEst.
May 18, 2026
Primary completionEst.
Jun 25, 2027
CompletionEst.
Jun 30, 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07598565
Responsible party
Emanuele Gallinoro (Principal Investigator, University of Roma La Sapienza) — Principal investigator
First posted
May 20, 2026
Start date
May 18, 2026 (estimated)
Primary completion
Jun 25, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
May 22, 2026

Study contacts

Emanuele Barbato, MD, PhD
Contact
emanuele.barbato@uniroma1.it
+39 06 3377 6115
Emanuele Gallinoro, MD, PhD
Contact
egallinoro@gmail.com
+39 06 3377 5005

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion